PT2734521T - Compostos tetra-hidropirrido-piridina e tetra-dropirridopirimidina e sua utilização como moduladores do recetor c5a - Google Patents

Compostos tetra-hidropirrido-piridina e tetra-dropirridopirimidina e sua utilização como moduladores do recetor c5a

Info

Publication number
PT2734521T
PT2734521T PT127430239T PT12743023T PT2734521T PT 2734521 T PT2734521 T PT 2734521T PT 127430239 T PT127430239 T PT 127430239T PT 12743023 T PT12743023 T PT 12743023T PT 2734521 T PT2734521 T PT 2734521T
Authority
PT
Portugal
Prior art keywords
tetrahydropyrido
pyridine
receptor modulators
pyrimidine compounds
pyrimidine
Prior art date
Application number
PT127430239T
Other languages
English (en)
Inventor
Gelin Christine
Flyer Alec
Michael Adams Christopher
Darsigny Veronique
Brian Hurley Timothy
Ganesh Karki Rajeshri
Ji Nan
Kawanami Toshio
Meredith Erik
H Serrano-Wu Michael
Rao Chang
Solovay Catherine
Tien-San Lee George
Towler Christopher
Har Denis
Shen Lichun
Hu Bin
Jiang Xinglong
Cappaci-Daniel Christina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46604083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2734521(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2734521T publication Critical patent/PT2734521T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT127430239T 2011-07-22 2012-07-20 Compostos tetra-hidropirrido-piridina e tetra-dropirridopirimidina e sua utilização como moduladores do recetor c5a PT2734521T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510643P 2011-07-22 2011-07-22
US201161539732P 2011-09-27 2011-09-27

Publications (1)

Publication Number Publication Date
PT2734521T true PT2734521T (pt) 2017-08-11

Family

ID=46604083

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127430239T PT2734521T (pt) 2011-07-22 2012-07-20 Compostos tetra-hidropirrido-piridina e tetra-dropirridopirimidina e sua utilização como moduladores do recetor c5a

Country Status (25)

Country Link
US (2) US8846656B2 (pt)
EP (1) EP2734521B1 (pt)
JP (1) JP6040237B2 (pt)
KR (1) KR20140096020A (pt)
CN (1) CN103814027B (pt)
AP (1) AP2014007398A0 (pt)
AR (1) AR087288A1 (pt)
AU (1) AU2012287183B2 (pt)
BR (1) BR112014001468A2 (pt)
CA (1) CA2842528A1 (pt)
CL (1) CL2014000171A1 (pt)
CO (1) CO6862157A2 (pt)
CR (1) CR20140032A (pt)
EA (1) EA201490320A1 (pt)
ES (1) ES2637167T3 (pt)
IL (1) IL230501A0 (pt)
MA (1) MA35275B1 (pt)
MX (1) MX336497B (pt)
PE (1) PE20141281A1 (pt)
PL (1) PL2734521T3 (pt)
PT (1) PT2734521T (pt)
TN (1) TN2014000030A1 (pt)
TW (1) TW201311688A (pt)
UY (1) UY34209A (pt)
WO (1) WO2013016197A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103108871B (zh) * 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MX2014013428A (es) * 2012-05-04 2015-02-04 Novartis Ag Moduladores de la ruta del complemento y usos de los mismos.
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105229003B (zh) * 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
PT2986610T (pt) 2013-04-19 2018-03-09 Incyte Holdings Corp Heterociclos bicíclicos como inibidores de fgfr
ES2946751T3 (es) 2013-10-24 2023-07-25 Univ Boston Sistema de infusión para prevenir la canalización incorrecta de múltiples medicamentos
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2019014292A (es) * 2017-05-31 2022-04-07 Chemocentryx Inc Anillos 5-5 fusionados como inhibidores c5a.
EP3630775B1 (en) * 2017-05-31 2022-12-14 ChemoCentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
CA3085835A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
EP3728202A4 (en) 2017-12-22 2021-05-26 ChemoCentryx, Inc. DIARYL-SUBSTITUTED 5,5-CONDENSED RING COMPOUNDS AS C5AR INHIBITORS
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
ES2933820T3 (es) * 2018-01-10 2023-02-14 Idorsia Pharmaceuticals Ltd Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidina-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de la vasculitis y las enfermedades inflamatorias
US11608336B2 (en) * 2018-04-02 2023-03-21 Chemocentryx, Inc. Prodrugs of fused-bicyclic C5aR antagonists
PE20210920A1 (es) 2018-05-04 2021-05-19 Incyte Corp Formas solidas de un inhibidor de fgfr y procesos para prepararlas
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4107146A1 (en) * 2020-02-17 2022-12-28 Alesta Therapeutics BV Gcn2 modulator compounds
CN116323623A (zh) 2020-09-18 2023-06-23 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
US20230382856A1 (en) * 2020-10-30 2023-11-30 Daiichi Sankyo Company, Limited Method of producing 3-methyl-4-halo-indole derivative
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4727149A (en) 1982-03-11 1988-02-23 John Wyeth & Brother Limited Preparation of nitriles of fused ring pyridine derivatives
US5853740A (en) 1996-08-07 1998-12-29 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils
AU2001290914A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2520465A1 (en) 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
AR045445A1 (es) * 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7482350B2 (en) 2004-05-08 2009-01-27 Neurogen Corporation 4,5-disubstituted-2-aryl pyrimidines
US7429666B2 (en) 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
AP2007003923A0 (en) 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
CN101273039A (zh) 2005-08-12 2008-09-24 默克公司 可用作p38激酶抑制剂的杂二环化合物
ES2348122T3 (es) 2006-04-20 2010-11-30 F. Hoffmann-La Roche Ag Derivados de diazepano moduladores de receptores de quimioquina.
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009023669A1 (en) 2007-08-13 2009-02-19 Janssen Pharmaceutica N.V. Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
UA101676C2 (uk) 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
US7989463B2 (en) 2008-09-03 2011-08-02 Dr. Reddy's Laboratories Limited Biccyclic compounds as GATA modulators
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US20120244192A1 (en) 2009-04-27 2012-09-27 Cook Gary P Sustained release formulations of peptidomimetic drugs and uses thereof
US8492392B2 (en) 2009-05-27 2013-07-23 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors
EP2467382B1 (en) 2009-08-17 2014-06-25 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine pde10 inhibitors
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AU2012315988A1 (en) 2011-09-30 2014-04-10 Kineta, Inc. Anti-viral compounds
WO2013082535A2 (en) 2011-12-02 2013-06-06 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof

Also Published As

Publication number Publication date
CR20140032A (es) 2014-05-16
EP2734521B1 (en) 2017-05-10
PL2734521T3 (pl) 2017-10-31
AP2014007398A0 (en) 2014-01-31
US20130184253A1 (en) 2013-07-18
PE20141281A1 (es) 2014-09-24
EP2734521A1 (en) 2014-05-28
CL2014000171A1 (es) 2014-10-03
US9505755B2 (en) 2016-11-29
MX336497B (es) 2016-01-21
AR087288A1 (es) 2014-03-12
AU2012287183B2 (en) 2014-11-20
IL230501A0 (en) 2014-03-31
MX2014000898A (es) 2014-02-19
CA2842528A1 (en) 2013-01-31
TN2014000030A1 (en) 2015-07-01
CN103814027A (zh) 2014-05-21
US8846656B2 (en) 2014-09-30
AU2012287183A1 (en) 2014-01-30
JP6040237B2 (ja) 2016-12-07
UY34209A (es) 2013-02-28
EA201490320A1 (ru) 2014-06-30
MA35275B1 (fr) 2014-07-03
CN103814027B (zh) 2016-07-06
ES2637167T3 (es) 2017-10-11
BR112014001468A2 (pt) 2017-01-10
US20140349995A1 (en) 2014-11-27
CO6862157A2 (es) 2014-02-10
KR20140096020A (ko) 2014-08-04
TW201311688A (zh) 2013-03-16
WO2013016197A1 (en) 2013-01-31
JP2014521607A (ja) 2014-08-28

Similar Documents

Publication Publication Date Title
IL230501A0 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and their use as a5c receptor modulators
GB2508204B (en) Orthosis
GB201213700D0 (en) Receptor antagnists II
EP2740774A4 (en) Dispersion
TWI560388B (en) Dampferzeugerheizrohrreparaturmittel und reparaturverfahren
IL251897A0 (en) X-receptor modulators of the liver
GB201111705D0 (en) Compounds and their use
PL3701800T3 (pl) Zastosowanie
EP2860236A4 (en) LIQUID CRYSTAL COMPOSITION
GB201004739D0 (en) Receptor modulators
HK1206333A1 (en) Liver receptor modulators
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
GB201111630D0 (en) Novel compounds and their use
LT2858606T (lt) Įtvaras
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
GB201214220D0 (en) Radiosynthesis
GB201111775D0 (en) Compounds and uses thereof
GB201114448D0 (en) Compounds and their use
GB201223053D0 (en) Receptor
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
AP3693A (en) Composition for anti-mosquito use
EP2805717A4 (en) CUTTING HUNGER
GB201109653D0 (en) Dispersion
GB201219451D0 (en) Tiling
GB201104444D0 (en) Compounds and their use